This is, for example, higher than an incremental cost-effectiveness ratios stated for an intervention promoting the use of hip protectors in nursing homes (about 1,200 EUR/fracture avoided) and lower than for the treatment of osteoporosis with bisphosphonates (≥11,016 EUR/fracture avoided)